Pfizer Issues Voluntary Nationwide Recall for Lots of Quinapril HCI Due to N-Nitroso-Quinapril Content

Pfizer voluntarily recalled 5 lots of quinapril HCI (Accupril) tablets distributed to the patient level as a result of the presence of the N-nitroso-quinapril nitrosamine, observed in recent testing over the acceptable daily intake (ADI) level.

Pfizer recalls Accupril

According to Pfizer press release, nitrosamines are common in water and numerous foods, such as cured and grilled meats, milk products, as well as vegetables. Although everyone is revealed to some degree of nitrosamines, these impurities can increase the chances of cancer in people subjected to them above appropriate degrees over extended periods of time.

Accupril is recommended for the treatment of hypertension as well as in the monitoring of cardiac arrest as adjunctive therapy when combined with conventional therapies, such as diuretics or digitalis. According to the press release, Accupril has a safety profile that has been established for more than three decades. To date, Pfizer is unaware of reports of adverse events evaluated to be connected to this recall.

According to the press release, Pfizer believes the benefit/risk profile of the items remains positive based on currently available information. Although a long-lasting intake of N-nitroso-quinapril may be related to a possible raised cancer threat in humans, there is no immediate risks to people taking this medication. Patients presently taking Accupril need to consult their healthcare provider regarding alternate treatment options.

The lot numbers recalled are DR9639, DX8682, DG1188, DX6031, and also CK6260. Wholesalers and distributors with an existing stock of these lots need to stop usage and distribution and should quarantine the products immediately, according to the press release. Patients taking the product should speak with their physician or pharmacist to identify whether they have the aforementioned product.

Read the original article on Pharmacy Times.

Related “Drug-Like Molecules Indicate New Strategies for Cancer Cells Therapy”

REFERENCE

Pfizer Voluntary Nationwide Recall of Great Deals Of Accupril (Quinapril HCI) Due to N-Nitroso-Quinapril Material. News release. Pfizer; April 22, 2022. Accessed April 25, 2022.